Highbridge Capital Management’s Amryt Pharma AMYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-6,333,552
Closed -$92.3M – 479
2023
Q1
$92.3M Hold
6,333,552
– – 3.4% 2
2022
Q4
$46.2M Hold
6,333,552
– – 1.27% 9
2022
Q3
$43.8M Hold
6,333,552
– – 0.62% 13
2022
Q2
$44.3M Buy
6,333,552
+273,552
+5% +$2.13M 1.01% 7
2022
Q1
$50.1M Buy
6,060,000
+4,198,474
+226% +$37.9M 1.16% 9
2021
Q4
$20.1M Buy
1,861,526
+227,160
+14% +$2.45M 0.44% 50
2021
Q3
$19.8M Buy
1,634,366
+960,965
+143% +$10.8M 0.52% 59
2021
Q2
$8.17M Sell
673,401
-339,023
-33% -$4.21M 0.23% 121
2021
Q1
$14.1M Buy
1,012,424
+185,994
+23% +$2.6M 0.56% 49
2020
Q4
$11.7M Buy
826,430
+150,396
+22% +$1.96M 0.45% 64
2020
Q3
$8.28M Buy
+676,034
New +$7.83M 0.45% 55

Highbridge Capital Management's AMYT Position: Q2 2023 in Review

Highbridge Capital Management sold out of Amryt Pharma (AMYT) in Q2 2023, closing a stake of 6,333,552 shares — an estimated $92.3M sold.

Highbridge Capital Management first reported a position in AMYT in Q3 2020 and held it in 11 quarters. The position peaked at $92.3M in Q1 2023. 0 funds tracked by Wall St. Rank hold AMYT as of Q2 2023.

  • Highbridge Capital Management reported no remaining Amryt Pharma position as of Q2 2023 after selling out during the quarter.
  • Highbridge Capital Management sold 6,333,552 Amryt Pharma shares in Q2 2023, an estimated $92.3M.
  • Highbridge Capital Management first reported a position in Amryt Pharma in Q3 2020 and held it in 11 quarters.
  • Highbridge Capital Management's Amryt Pharma position peaked at $92.3M in Q1 2023.
  • 0 funds tracked by Wall St. Rank held Amryt Pharma as of Q2 2023.

Based on Highbridge Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.